CONTENTS (cont'd)

JAMES M. FORD, WALTER C. PROZIALECK, AND WILLIAM N. HAIT. Structural Features Determining Activity of Phenothiazines and Related Drugs for Inhibition of Cell Growth and Reversal of Multidrug Resistance .................................................. 105

JOHN M. THOMAS AND BRIAN B. HOFFMAN. Chronic Somatostatin Treatment Induces Enhanced Forskolin-Stimulated cAMP Accumulation in Wild-Type S49 Mouse Lymphoma Cells But Not in Protein Kinase-Deficient Mutants ........................................... 116

RICHARD F. COX AND BARBARA L. WASZCZAK. Differences in Dopamine Receptor Reserve for N-n-Propylnorapomorphine Enantiomers: Single Unit Recording Studies after Partial Inactivation of Receptors by N-Ethoxycarbonyl-2-ethoxy-1, 2-dihydroquinoline .......................................................... 125

ANNE H. CHEUNG, IRVING S. SIGAL, RICHARD A. F. DIXON, AND CATHERINE D. STRADER. Agonist-Promoted Sequestration of the β2-Adrenergic Receptor Requires Regions Involved in Functional Coupling with Gs ........................................... 132

PATRICK H. ROSEBOOM AND MARGARET C. GNEGY. Acute In Vitro Amphetamine Produces a Homologous Desensitization of Dopamine Receptor-Coupled Adenylate Cyclase Activities and Decreases Agonist Binding to the D1 Site ........................................... 139

JAMES HALPERT, JOHN-YAN JAW, AND CELIA BALFOUR. Specific Inactivation by 17ß-Substituted Steroids of Rabbit and Rat Liver Cytochromes P-450 Responsible for Progesterone 21-Hydroxylation .................................................. 148

JAMES D. HIRSCH, CARL F. BEYER, LORRAINE MALKOWITZ, BERNARD BEER, AND ARTHUR J. BLUME. Mitochondrial Benzodiazepine Receptors Mediate Inhibition of Mitochondrial Respiratory Control ........................................... 157

JAMES D. HIRSCH, CARL F. BEYER, LORRAINE MALKOWITZ, COSTAS C. LOULLIS, AND ARTHUR J. BLUME. Characterization of Ligand Binding to Mitochondrial Benzodiazepine Receptors ........................................... 164

Copyright © 1989 by The American Society for Pharmacology and Experimental Therapeutics
All Rights Reserved

No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing from the copyright owner.

The appearance of the code at the bottom of the first page of an article in this journal indicates the copyright owner's consent that copies of this article may be made for personal or internal use, or for the personal or internal use of specific clients. This consent is given on the condition, however, that the copier pay the stated per copy fee through the Copyright Clearance Center, Inc., (21 Congress Street, Salem, Massachusetts 01970), for copying beyond that permitted by Sections 107 or 108 of the U.S. Copyright Law. This consent does not extend to other kinds of copying, such as copying for general distribution, for advertising or promotional purposes, for creating new collective works or for resale. Copy fees for pre-1986 articles are the same as those shown for current articles.